Format

Send to

Choose Destination
Semin Oncol. 2016 Feb;43(1):173-188. doi: 10.1053/j.seminoncol.2015.09.011. Epub 2015 Sep 8.

Cancer prevention in HIV-infected populations.

Author information

1
HIV & AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
2
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
3
HIV & AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: uldrickts@mail.nih.gov.

Abstract

People living with human immunodeficiency virus (HIV) are living longer since the advent of effective combined antiretroviral therapy (cART). While cART substantially decreases the risk of developing some cancers, HIV-infected individuals remain at high risk for Kaposi sarcoma, lymphoma, and several solid tumors. Currently HIV-infected patients represent an aging group, and malignancies have become a leading cause of morbidity and mortality. Tailored cancer-prevention strategies are needed for this population. In this review we describe the etiologic agents and pathogenesis of common malignancies in the setting of HIV, as well as current evidence for cancer prevention strategies and screening programs.

KEYWORDS:

AIDS-related lymphoma; HIV; HPV vaccines; Kaposi sarcoma; Neoplasms

PMID:
26970136
PMCID:
PMC4789150
DOI:
10.1053/j.seminoncol.2015.09.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center